Recent news highlights that RPG Life Sciences has formed a dedicated active pharmaceutical ingredient (API) subsidiary platform called RPG Active Pharma and partnered with healthcare-focused investor InvAscent, committing up to ₹700 crore to expand manufacturing capabilities and drive strategic acquisitions. Additionally, the company reported strong financial updates, including solid quarterly revenue growth and plans to expand into high-value therapy lines.